Arcellx, Inc. (ACLX)

They are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. They recently announced positive preliminary results from their ongoing Phase 1 clinical trial of CART-ddBCMA, their lead ddCAR product candidate, for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM), defined as patients with either minimal response or disease progression within 60 days of last treatment. As of the November 4, 2021 data cutoff date, of the 24 patients who had been dosed, 22 were evaluable for safety analysis and 19 were evaluable for efficacy analysis, based on follow-up of at least 1 and 3 months, respectively, following treatment using the 2016 International Myeloma Working Group (IMWG) uniform response criteria for MM. These evaluable patients comprised the dose escalation cohorts for the first dose level (DL1) (n=6) and the second dose level (DL2) (n=6) and a dose expansion cohort of DL1 (safety n=10, efficacy n=7).

Industry
Cell Therapy - Immunotherapies

CEO	CFO
-

Employees	Founded
78	2014

Address: 25 West Watkins Mill Road, Suite A Gaithersburg, Md 20878

Telephone: (240) 327-0603

Web page: http://www.arcellx.com

First Trade Date	2/4/2022
Status	Priced
Exchange	NASDAQ
Lockup Period Expiration	.Pro
Quiet Period Expiration	.Pro
Old Price Range	-

Share prices ($)

What do you think will happen with the ACLX share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

The lead left underwriter: BofA Securities

Over the last 12 months Since the beginning of the year

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

IPOs led by the firm	.Pro
Profitability of conducted IPOs  ?	.Pro
1st day change  ?	.Pro
Change for the first 3 months  ?	.Pro

Underwriters
BofA Securities/ SVB Leerink/ Barclays/ William Blair
CO-Managers